Evidence map›Paper›PMID 38326275›Full record

ArticleEpidemiology and infection2024

COVID-19 passenger screening to reduce travel risk and translocation of disease.

Lindsay L Waite, Ahmad Nahhas, Jan Irvahn, Grace Garden, Caroline M Kerfonta, Elizabeth Killelea, William Ferng, Joshua J Cummins, Rebecca Mereness, Thomas Austin and 7 more

Open access · goldAbstract read
In one paragraph

Article in Epidemiology and infection, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 98% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 1 institution in 1 country.

Lindsay L WaiteThe Boeing Company, Arlington, Virginia, United States.
Ahmad NahhasThe Boeing Company, Arlington, Virginia, United States.
Jan IrvahnThe Boeing Company, Arlington, Virginia, United States.
Grace GardenThe Boeing Company, Arlington, Virginia, United States.
Caroline M KerfontaThe Boeing Company, Arlington, Virginia, United States.
Elizabeth KilleleaThe Boeing Company, Arlington, Virginia, United States.
William FerngThe Boeing Company, Arlington, Virginia, United States.
Joshua J CumminsThe Boeing Company, Arlington, Virginia, United States.
Rebecca MerenessThe Boeing Company, Arlington, Virginia, United States.
Thomas AustinThe Boeing Company, Arlington, Virginia, United States.
Stephen JonesThe Boeing Company, Arlington, Virginia, United States.
Nels OlsonThe Boeing Company, Arlington, Virginia, United States.
Mark WilsonThe Boeing Company, Arlington, Virginia, United States.
Benson IsaacThe Boeing Company, Arlington, Virginia, United States.
Craig A PepperThe Boeing Company, Arlington, Virginia, United States.
Iain S KoolhofThe Boeing Company, Arlington, Virginia, United States.ORCID 0000-0002-9923-7416
Jason ArmstrongThe Boeing Company, Arlington, Virginia, United States.
Boeing (Australia) · AU

Funding

The Boeing Company
6 · The paper itself

Abstract

Aviation passenger screening has been used worldwide to mitigate the translocation risk of SARS-CoV-2. We present a model that evaluates factors in screening strategies used in air travel and assess their relative sensitivity and importance in identifying infectious passengers. We use adapted Monte Carlo simulations to produce hypothetical disease timelines for the Omicron variant of SARS-CoV-2 for travelling passengers. Screening strategy factors assessed include having one or two RT-PCR and/or antigen tests prior to departure and/or post-arrival, and quarantine length and compliance upon arrival. One or more post-arrival tests and high quarantine compliance were the most important factors in reducing pathogen translocation. Screening that combines quarantine and post-arrival testing can shorten the length of quarantine for travelers, and variability and mean testing sensitivity in post-arrival RT-PCR and antigen tests decrease and increase with the greater time between the first and second post-arrival test, respectively. This study provides insight into the role various screening strategy factors have in preventing the translocation of infectious diseases and a flexible framework adaptable to other existing or emerging diseases. Such findings may help in public health policy and decision-making in present and future evidence-based practices for passenger screening and pandemic preparedness.

Indexed as

Air TravelCOVID-19HumansMonte Carlo MethodSARS-CoV-2airportaviationCOVID-19disease transmissionpandemicquarantineRT-PCRscreening

Identifiers

PMID38326275
PMCPMC10945944
OpenAlexW4391649003

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.